NCT02194777
Completed
Phase 1
A Double-blind (at Each Dose Level), Randomised, Placebo-controlled Single Increasing Dose Safety, Tolerability and Pharmacokinetics Study in Healthy Male and Female Volunteers After Inhalative Administration of BIBN 4096 BS (Dosage: 5 - 80 mg)
ConditionsHealthy
Overview
- Phase
- Phase 1
- Intervention
- BIBN 4096 BS - in single rising doses
- Conditions
- Healthy
- Sponsor
- Boehringer Ingelheim
- Enrollment
- 48
- Primary Endpoint
- Number of patients with adverse events
- Status
- Completed
- Last Updated
- 11 years ago
Overview
Brief Summary
The objective of the present study is to obtain information about the safety, tolerability and pharmacokinetics of BIBN 4096 BS after single inhalative administration of increasing doses in healthy male and female volunteers
Investigators
Eligibility Criteria
Inclusion Criteria
- •Participants should be healthy males and females
- •Age range from 21 to 50 years
- •(Broca-Index): within +-20% of their normal weight
- •In accordance with Good Clinical Practice (GCP) and local legislation all volunteers are supposed to give their written informed consent prior to admission to the study
- •As part of the screening (within 14 days before drug administration), each subject was to receive a complete medical examination (including blood pressure, pulse rate, medical history, documentation of demographics, inclusion/exclusion criteria and concomitant therapy) as well as a 12-lead Electrocardiogram (ECG) and a lung function test (Raw, SGaw). Moreover laboratory parameters (including drug screening, HBs-antigen (HBs-Ag), anti HBc-antibodies, anti HCV- antibodies and Human immunodeficiency virus (HIV) test as well as pregnancy test for female subjects are to be determined
Exclusion Criteria
- •Any finding of the medical examination (including blood pressure, pulse rate and ECG) deviating from normal and of clinical relevance
- •Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
- •Diseases of the central nervous system (such as epilepsy) or with psychiatric disorders or neurological disorders
- •History of orthostatic hypotension, fainting spells or blackouts
- •Chronic or relevant acute infections
- •History of allergy/hypersensitivity (including drug allergy) which is deemed relevant to the trial as judged by the investigator
- •Intake of a drug with a long half-life (\> 24 hours) within at least 1 month or less than ten half-lives of the respective drug before enrolment in the study (except substitution therapy regarding thyroid gland/or ovaries)
- •Use of any drugs which might influence the results of the trial within 1 week prior to administration or during the trial
- •Participation in another study with an investigational drug within two months prior to administration or during the trial
- •Smoker (\> 10 cigarettes or \> 3 cigars or \> 3 pipes/day)
Arms & Interventions
BIBN 4096 BS - in single rising doses
Intervention: BIBN 4096 BS - in single rising doses
Placebo
Intervention: Placebo
Outcomes
Primary Outcomes
Number of patients with adverse events
Time Frame: up to 24 days
Number of patients with clinically relevant changes in Blood Pressure
Time Frame: up to 24 days
Number of patients with clinically relevant changes in Pulse Rate
Time Frame: up to 24 days
Number of patients with clinically relevant changes in standard laboratory evaluation
Time Frame: up to 24 days
Assessment of tolerability on a 4-point scale
Time Frame: 8 days after drug administration
Number of patients with clinically relevant changes in Electrocardiogram
Time Frame: up to 24 days
Change in lung function measurement specific conductance (SGaw)
Time Frame: up to 5 hours after drug administration
Change in lung function measurement airway resistance (Raw)
Time Frame: up to 5 hours after drug administration
Secondary Outcomes
- tmax (Time from dosing to the maximum concentration of the analyte in plasma)(up to 48 hours after drug administration)
- MRTtot (Total mean residence time of the analyte molecules in the body)(up to 48 hours after drug administration)
- CL/F (Apparent clearance of the analyte in plasma following extravascular administration)(up to 48 hours after drug administration)
- Vz/F (Apparent volume of distribution of the analyte during the terminal phase)(up to 48 hours after drug administration)
- AUC0-tz (Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point)(up to 48 hours after drug administration)
- λz (Terminal rate constant in plasma)(up to 48 hours after drug administration)
- t½ (Terminal half-life of the analyte in plasma)(up to 48 hours after drug administration)
- Cmax (Maximum measured concentration of the analyte in plasma)(up to 48 hours after drug administration)
- AUC0-∞ (Area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity)(up to 48 hours after drug administration)
- Ae (Amount of parent drug excreted into urine)(up to 24 hours after drug administration)
- CLR (Renal clearance of the analyte in plasma)(up to 48 hours after drug administration)
Similar Trials
Completed
Phase 1
Safety, Tolerability and Pharmacokinetics After Administration of Increasing Dose of BIBN 4096 BS in Healthy Male and Female VolunteersHealthyNCT02194322Boehringer Ingelheim38
Completed
Phase 1
Single Rising Dose Study Investigating the Safety, Tolerability and Pharmacokinetics of Spray Dried BIBN 4096 BS After Inhalation Administration in Healthy Male and Female VolunteersHealthyNCT02199860Boehringer Ingelheim63
Completed
Phase 1
Safety, Tolerability and Pharmacokinetics of Increasing Doses of BIBN 4096 BS in Healthy Male and Female VolunteersHealthyNCT02194335Boehringer Ingelheim32
Completed
Phase 1
Study to Determine Tolerability of Single Increasing Dose of BIBN 4096 BS in Healthy Male and Female VolunteersHealthyNCT02194348Boehringer Ingelheim12
Completed
Phase 1
Single Rising Dose Tolerability Study of BIBN 4096 BS in Healthy Male and Female VolunteersHealthyNCT02198326Boehringer Ingelheim32